Melnyk N. Clinical and genetic features of obese patients in combination with non-alcoholic fatty liver disease and optimization of their treatment

This thesis is devoted to the improvement of treatment of obese patients in combination with non-alcoholic fatty liver disease (NAFLD) by studying the clinical and genetic characteristics of patients and personification of treatment based on polymorphism Pro12Ala (rs1801282) in the PPAR-γ2 gene and clinical data. Investigation assignment: 1. To study the clinical and genetic characteristics (degree of hepatic steatosis, anthropometric parameters, indicators of arterial pressure and heart rate, biochemical parameters, lipid profile and oral glucose tolerance test (OGTT) with simultaneous determination of insulin and C-peptide, the genotype PPAR-γ2 Pro12Ala (rs1801282) polymorphism) of obese patients in combination with non-alcoholic fatty liver 2. To investigate anamnestic data on obesity and adherence to treatment in patients with obesity in combination with non-alcoholic fatty liver disease 3. To evaluate the effectiveness of drug therapy of non-alcoholic fatty liver disease on the background of obesity in a daily dose of pioglitazone 15 mg during 12 weeks of treatment 4. To identify the dependence between indicators of the degree of hepatic steatosis, body mass index and OGTT with simultaneous determination of insulin and C-peptide, ferritin, uric acid and the dynamic of their reduction depending on the genotype PPAR-γ2 Pro12Ala (rs1801282) polymorphism, during 12 weeks of treatment of obese patients and non-alcoholic fatty liver 5. To study the effectiveness of personalized treatment of patients with obesity and non-alcoholic fatty liver disease depending on pioglitazone in the treatment, PPAR-γ2 rs1801282 polymorphism, primary indicators of ultrasound steatometry and features of the anamnesis of obesity.